Find Capivasertib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Azd5363, 1143532-39-1, Azd-5363, Azd 5363, (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
Molecular Formula
C21H25ClN6O2
Molecular Weight
428.9  g/mol
InChI Key
JDUBGYFRJFOXQC-KRWDZBQOSA-N
FDA UNII
WFR23M21IE

Capivasertib
Capivasertib is a novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.
1 2D Structure

Capivasertib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
2.1.2 InChI
InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1
2.1.3 InChI Key
JDUBGYFRJFOXQC-KRWDZBQOSA-N
2.1.4 Canonical SMILES
C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4
2.1.5 Isomeric SMILES
C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4
2.2 Other Identifiers
2.2.1 UNII
WFR23M21IE
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide

2. Azd5363

2.3.2 Depositor-Supplied Synonyms

1. Azd5363

2. 1143532-39-1

3. Azd-5363

4. Azd 5363

5. (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

6. 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

7. Wfr23m21ie

8. 4-piperidinecarboxamide, 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-

9. 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide

10. Unii-wfr23m21ie

11. Chembl2325741

12. Cc-638

13. Capivasertib?

14. 4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide

15. 4-piperidinecarboxamide, 4-amino-n-((1s)-1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-

16. Capivasertib (jan/usan)

17. Capivasertib [inn]

18. Capivasertib [jan]

19. Capivasertib [usan]

20. Capivasertib (azd5363)

21. Mls006011179

22. Capivasertib [who-dd]

23. Schembl390243

24. Gtpl7709

25. Azc5363

26. Dtxsid40150710

27. Ex-a285

28. Us10654855, Example 9

29. Bdbm443385

30. Mfcd22628785

31. Nsc764039

32. Nsc782347

33. Nsc799347

34. S8019

35. Zinc43204023

36. Akos027323693

37. Bcp9000365

38. Ccg-268989

39. Cs-1284

40. Db12218

41. Nsc-764039

42. Nsc-782347

43. Nsc-799347

44. Ncgc00345795-01

45. Ncgc00345795-04

46. Ac-32685

47. Hy-15431

48. Smr004702948

49. Bcp0726000111

50. A1387

51. Sw220158-1

52. D11371

53. J-514447

54. Q27074756

55. 0xz

56. 4-amino-n-((1s)-1-(4-chlorophenyl)-3-hydroxypropyl)-1- (1h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide

57. Alternative Route 1: (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

2.4 Create Date
2009-04-28
3 Chemical and Physical Properties
Molecular Weight 428.9 g/mol
Molecular Formula C21H25ClN6O2
XLogP31.7
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count6
Rotatable Bond Count6
Exact Mass428.1727518 g/mol
Monoisotopic Mass428.1727518 g/mol
Topological Polar Surface Area120 Ų
Heavy Atom Count30
Formal Charge0
Complexity580
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of breast cancer , Treatment of prostate cancer


API SUPPLIERS

read-more
read-more

01

Biophore India Pharmaceuticals Pvt...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Biophore

02

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Dr Reddy Company Banner

03

Egis Pharmaceuticals PLC

Hungary

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

Flag Hungary
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Egis Pharmaceuticals

04

Shandong Chenghui Shuangda Pharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChina’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Shandong Chenghui Shuangda Pharmaceutical

05

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
TAPI Company Banner

06

Daishang Pharmchem Group

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Daishang Pharmchem Group

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Sichuan Taienkang Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Sichuan Taienkang Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Macleods Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

09

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Capivasertib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.


Lead Product(s): Capivasertib,Loperamide Hydrochloride,Fulvestrant,Cetirizine

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: AstraZeneca

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 23, 2026

blank

01

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Capivasertib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 23, 2026

blank

Details:

Capivasertib is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of liver diseases.


Lead Product(s): Capivasertib,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: PAREXEL International Corporation

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 15, 2026

blank

02

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Capivasertib is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of liver diseases.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 15, 2026

blank

Details:

AMXT 1501 Dicaprate is a small molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Melanoma.


Lead Product(s): AMXT-1501 dicaprate,Eflornithine Hydrochloride,Fulvestrant,Capivasertib,Pembrolizumab

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 17, 2025

blank

03

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : AMXT 1501 Dicaprate is a small molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Melanoma.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 17, 2025

blank
  • Development Update

Details:

Capivasertib is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Breast Neoplasms.


Lead Product(s): Capivasertib,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: AstraZeneca

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 15, 2025

blank

04

West German Study Group

Country
arrow
PEGS Boston Summit
Not Confirmed

West German Study Group

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Capivasertib is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Breast Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 15, 2025

blank

Details:

Dextromethorphan is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Dextromethorphan,Capivasertib

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: PAREXEL International Corporation

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 21, 2025

blank

05

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Dextromethorphan is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 21, 2025

blank
  • Development Update

Details:

Capivasertib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Leukemia, Lymphoid.


Lead Product(s): Capivasertib,Venetoclax,Dexamethasone,Methotrexate,Prednisone,Hydrocortisone,Cytarabine

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

Sponsor: AstraZeneca | AbbVie Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 16, 2025

blank

06

Princess Maxima Center for Pediatric Oncology

Country
arrow
PEGS Boston Summit
Not Confirmed

Princess Maxima Center for Pediatric Oncology

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Capivasertib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Leukemia, Lymphoid.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 16, 2025

blank

Details:

Capivasertib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.


Lead Product(s): Capivasertib,Rosuvastatin Calcium

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Parexel

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 28, 2025

blank

07

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Capivasertib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 28, 2025

blank

Details:

Truqap (capivasertib) is a first-in-class, potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms. Currently, it is being evaluated for treatment of mCRPC.


Lead Product(s): Capivasertib,Docetaxel

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 29, 2025

blank

08

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Truqap (capivasertib) is a first-in-class, potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms. Currently, it is being evaluated for treatment of mCRPC.

Product Name : Truqap

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 29, 2025

blank

Details:

Fulvestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.


Lead Product(s): Fulvestrant,Capivasertib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Apices Soluciones | SOLTI Breast Cancer Research Group

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 08, 2025

blank

09

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Fulvestrant,Capivasertib

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Apices Soluciones | SOLTI Breast Cancer Research Group

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Fulvestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 08, 2025

blank

Details:

Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor, is being investigated for PTEN-deficient de novo mHSPC in combination with abiraterone and ADT.


Lead Product(s): Capivasertib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 25, 2024

blank

10

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor, is being investigated for PTEN-deficient de novo mHSPC in combination with abiraterone and ADT.

Product Name : Truqap

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 25, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
PEGS Boston Summit
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

CAPIVASERTIB

US Patent Number : 8101623

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 218197

Patent Use Code : U-3762

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-03-10

blank

02

arrow
PEGS Boston Summit
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

CAPIVASERTIB

US Patent Number : 12252495

Drug Substance Claim :

Drug Product Claim :

Application Number : 218197

Patent Use Code : U-3762

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-10-10

blank

03

arrow
PEGS Boston Summit
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

CAPIVASERTIB

US Patent Number : 12252495

Drug Substance Claim :

Drug Product Claim :

Application Number : 218197

Patent Use Code : U-3762

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-10-10

blank

04

arrow
PEGS Boston Summit
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

CAPIVASERTIB

US Patent Number : 10059714

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 218197

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-10-10

blank

05

arrow
PEGS Boston Summit
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

CAPIVASERTIB

US Patent Number : 11760760

Drug Substance Claim :

Drug Product Claim :

Application Number : 218197

Patent Use Code : U-3762

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-10-10

blank

06

arrow
PEGS Boston Summit
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

CAPIVASERTIB

US Patent Number : 10059714

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 218197

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-10-10

blank

07

arrow
PEGS Boston Summit
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

CAPIVASERTIB

US Patent Number : 11760760

Drug Substance Claim :

Drug Product Claim :

Application Number : 218197

Patent Use Code : U-3762

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-10-10

blank

08

arrow
PEGS Boston Summit
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

CAPIVASERTIB

US Patent Number : 9487525

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 218197

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-04-16

blank

09

arrow
PEGS Boston Summit
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

CAPIVASERTIB

US Patent Number : 10654855

Drug Substance Claim :

Drug Product Claim :

Application Number : 218197

Patent Use Code : U-3762

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-10-10

blank

10

arrow
PEGS Boston Summit
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

CAPIVASERTIB

US Patent Number : 9487525

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 218197

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-04-16

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 1143532-39-1 / Capivasertib API manufacturers, exporters & distributors?

Capivasertib manufacturers, exporters & distributors 1

14

PharmaCompass offers a list of Capivasertib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Capivasertib manufacturer or Capivasertib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Capivasertib manufacturer or Capivasertib supplier.

API | Excipient name

Capivasertib

Synonyms

Azd5363, 1143532-39-1, Azd-5363, Azd 5363, (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

Cas Number

1143532-39-1

Unique Ingredient Identifier (UNII)

WFR23M21IE

About Capivasertib

Capivasertib is a novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.

Capivasertib Manufacturers

A Capivasertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Capivasertib, including repackagers and relabelers. The FDA regulates Capivasertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Capivasertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Capivasertib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Capivasertib Suppliers

A Capivasertib supplier is an individual or a company that provides Capivasertib active pharmaceutical ingredient (API) or Capivasertib finished formulations upon request. The Capivasertib suppliers may include Capivasertib API manufacturers, exporters, distributors and traders.

click here to find a list of Capivasertib suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Capivasertib USDMF

A Capivasertib DMF (Drug Master File) is a document detailing the whole manufacturing process of Capivasertib active pharmaceutical ingredient (API) in detail. Different forms of Capivasertib DMFs exist exist since differing nations have different regulations, such as Capivasertib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Capivasertib DMF submitted to regulatory agencies in the US is known as a USDMF. Capivasertib USDMF includes data on Capivasertib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Capivasertib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Capivasertib suppliers with USDMF on PharmaCompass.

Capivasertib GMP

Capivasertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Capivasertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Capivasertib GMP manufacturer or Capivasertib GMP API supplier for your needs.

Capivasertib CoA

A Capivasertib CoA (Certificate of Analysis) is a formal document that attests to Capivasertib's compliance with Capivasertib specifications and serves as a tool for batch-level quality control.

Capivasertib CoA mostly includes findings from lab analyses of a specific batch. For each Capivasertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Capivasertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Capivasertib EP), Capivasertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Capivasertib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty